Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated
with a risk of potentially blinding complications such as retinal detachment and myopic
maculopathy. There is a direct association between the degree of myopia and the risk of
complications. Myopia develops in childhood and during adolescence. To prevent higher degrees
of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine
eye drops have been shown to reduce myopia progression by 50% in Asian populations but its
effect in non-Asian populations is unknown. The aim of this study is to investigate if
low-dose atropine can reduce myopia progression in Danish children and teenagers. The study
is an investigator initiated randomized clinical trial conducted as a collaboration between
three Danish Eye Departments covering all of Denmark.